Cost Utility of Adjuvant and Neo-Adjuvant Treatment for Breast Cancer: A Systematic Review of Observational Economic Evaluations Study

Luh Putu Febryana Larasanty; Irfanianta Arif Setyawan; Diah Nurlita

doi:10.24071/jpsc.007988

Cost Utility of Adjuvant and Neo-Adjuvant Treatment for Breast Cancer: A Systematic Review of Observational Economic Evaluations Study

Luh Putu Febryana Larasanty^(1*), Irfanianta Arif Setyawan⁽²⁾, Diah Nurlita⁽³⁾,

(1) Udayana University, Bali, Indonesia.
(2) Institut Teknologi Sumatera, Lampung, Indonesia
(3) Poltekkes Kemenkes Tasikmalaya, Tasikmalaya, Indonesia
(*) Corresponding Author

Abstract

This study aimed to perform a systematic review of an observational cost-utility analysis of adjuvant and neo-adjuvant agents in breast cancer patients. The PRISMA flowchart was used to conduct the literature search and study selection. Through the use of two databases, PubMed and Scopus, a literature search was done. The eligible study was determined based on the established inclusion criteria. To evaluate the quality of the study, Drummond's checklist was used. Data extraction was conducted to assess characteristics, study perspective, cost and outcome measurement, the cost-utility ratio in ICER value, threshold, sensitivity or probability analysis, and the conclusion of the cost-utility study. There was a total of 7 studies included for review. Four studies compared chemotherapy regimens as adjuvant or neoadjuvant and three studies included hormone therapy or targeted therapy as an intervention that compared. Observational characteristic includes the use of cohort methods, and a large number of participants, the comparison is mostly for adjuvant therapy purposes and direct medical cost measured from a payer perspective. Anthracycline-based chemotherapy like the FAC regimen showed potential cost-effectiveness results. The use of targeted therapy (pertuzumab, trastuzumab) and hormonal therapy (goserelin) is associated with better utility outcomes and an increase in cost burden from intervention. Based to the reviewed studies, anthracycline-containing regimens such as FAC may have pharmacoeconomic properties as adjuvant or neo-adjuvant therapy. While the use of the most recent pharmacological drug has the potential to improve utility outcomes, but is associated with an increase in the intervention's cost burden.

Keywords

breast cancer; cost-utility analysis; drug regimen; ICER; QALYs

References

Anampa, J., Makower, D., Sparano, J.A., 2015, Progress in Adjuvant Chemotherapy for Breast Cancer: an Overview, BMC Med, 13, 195.

Bastani, P., Kiadaliri, A.A., 2012. Cost-Utility Analysis of Adjuvant Therapies for Breast Cancer in Iran. Int J Technol Assess Health Care, 28(2), 110-4.

Bodrogi, J., Kaló, Z., 2010, Principles of Pharmacoeconomics and Their Impact on Strategic Imperatives of Pharmaceutical Research and Development. Br J Pharmacol, 159(7), 1367-73.

Cheng, T.F., Wang, J.D., Uen, W.C., 2012, Cost-Utility Analysis of Adjuvant Goserelin (Zoladex) and Adjuvant Chemotherapy in Premenopausal Women with Breast Cancer. BMC Cancer, 12, 33.

Ciruelos, E., Alba, E., López, R., et al, 2019, Contribution of Trastuzumab to the Prognostic Improvement of HER2-Positive Early Breast Cancer in Spain: an Estimation of Life Years and Disease-Free Life Years Gained Since its Approval. Oncotarget, 10(42), 4321-32.

Dai, W.F., Beca, J.M., Nagamuthu, C,. et al, 2022, COST-Effectiveness Analysis of Pertuzumab with Trastuzumab in Patients with Metastatic Breast Cancer. JAMA Oncol, 8(4), 597-606.

Ding, W., Li, Z., Wang, C., et al, 2018, Anthracycline Versus Nonanthracycline Adjuvant Therapy for Early Breast Cancer: a Systematic Review and Meta-Analysis, Medicine (Baltimore), 97(42), e12908.

Drummond, M.F., Schulper, M.J., Claxton, K., Stoddart, G.L., Torrance, G.W., 2015, Critical Assessment of Economic Evaluation. in “Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford University Press Oxford pp 41-44.

Eldawlatly, A., Alshehri, H., Alqahtani, A., et al, 2018, Appearance of Population, Intervention, Comparison, and Outcome as Research Question in the Title of Articles of Three Different Anesthesia Journals: a Pilot Study, Saudi J Anaesth, 12(2), 283-86.

Ferlay, J., Colombet, M., Soerjomataram, I., et al, 2019, Estimating the Global Cancer Incidence and Mortality in 2018: Globocan Sources and Methods. Int J Cancer, 144(8), 1941-53.

Hatam, N., Askarian, M., Javan-Noghabi, J., Ahmadloo, N., Mohammadianpanah, M., 2015, Cost-Utility of "Doxorubicin and Cyclophosphamide" Versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran. Asian Pac J Cancer Prev, 16(18), 8265-70.

Jasra, S., Anampa, J., 2018, Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review. Curr Treat Options Oncol, 19(6), 30.

Jayasekera, J., Mandelblatt, J.S., 2020, Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions, J Clin Oncol, 38(4), 332-50.

Kerr, A.J., Dodwell, D., McGale, P., et al, 2022, Adjuvant and Neoadjuvant Breast Cancer Treatments: a Systematic Review of Their Effects on Mortality. Cancer Treat Rev, 105, 1-12.

Lairson, D.R., Parikh, R.C., Cormier, J.N., Chan, W., Du, X.L., 2015, Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women, Value Health, 18(8), 1070-8.

Masoud, V., Pagès, G., 2017, Targeted Therapies in Breast Cancer: New Challenges to Fight Against Resistance, World J Clin Oncol, 8(2), 120-134.

Nerich, V., Saing, S., Gamper, E.M., et al, 2016, Cost-Utility Analyses of Drug Therapies in Breast Cancer: a Systematic Review, Breast Cancer Res Treat, 159(3), 407-24.

Nounou, M.I., ElAmrawy, F., Ahmed, N., et al, 2015, Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. Breast Cancer (Auckl), 9(Suppl 2), 17-34.

Peto, R., Davies, C., Godwin, J., et al, 2012, Early Breast Cancer Trialists’ Collaborative Group: Comparisons Between Different Polychemotherapy Regimens for Early Breast Cancer: Meta-Analyses of Long-Term Outcome Among 100,000 Women In 123 Randomised Trials, Lancet, 379(9814), 432-44.

Saptaningsih, A.B., Nikmah, U.S., Aryandono, T., Dwiprahasto, I., At Thobari, J., 2022, Cost-Effectiveness Analysis of Two Chemotherapy Regiments FAC Vs. Taxane for Operable Breast Cancer Patients in Indonesia, Asian Pac J Cancer Prev, 23(4), 1147-54.

Shien, T., Iwata, H., 2020, Adjuvant and Neoadjuvant Therapy for Breast Cancer, Jpn J Clin Oncol, 50(3), 225-229.

Spring, L.M., Gupta, A., Reynolds, K.L., et al, 2016, Neoadjuvant Endocrine Therapy For Estrogen Receptor-Positive Breast Cancer: A Systematic Review And Meta-Analysis. JAMA Oncol, 2(11), 1477-86.

Winn, A.N., Ekwueme, D.U., Guy, G.P., Neumann, P.J., 2016, COST-UTILITY ANALYSIS OF CANCER PREVENTION, TREATMENT, AND CONTROL: A SYSTEMATIC REVIEW. Am J Prev, 50(2), 241-8.

Wöckel, A., Albert, U.S., Janni, W., et al, 2018, The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer, Dtsch Arztebl Int, 115(18), 316-23.

DOI: https://doi.org/10.24071/jpsc.007988